ABUS vs LYFT
Arbutus Biopharma Corp (ABUS) versus LYFT Inc (LYFT) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
LYFT Inc (LYFT) is a software - application company listed on US. It is led by David Risher.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LYFT revenue for 2024-12-31 was $5.79B. Net income was $22.8M. Revenue was up 31.4% from 2023-12-31 to 2024-12-31. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LYFT currently screens at market cap $6.79B and trailing P/E 107.7.
Not investment advice. Open the ABUS and LYFT stock pages for the full models.
Not investment advice.